The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the third day of the meeting.

EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.

One of the few silver linings in a tumultuous year dominated by a global pandemic was the huge boost given to the diagnostics and telehealth sectors. But while new technologies for rapid testing for COVID-19 and remote monitoring tools dominated the headlines, there were also key developments in robotic surgery, early-stage cancer testing and cardiac arrhythmia treatment. Here are Medtech Insight’s most popular R&D stories in 2020.

The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.